Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

被引：0
|
作者：
Vipul Kumar
Edgar L. Schuck
Robert D. Pelletier
Nadia Farah
Krista B. Condon
Meng Ye
Christopher Rowbottom
Belinda M. King
Zhi-Yi Zhang
Philip L. Saxton
Y. Nancy Wong
机构：
[1] Cubist Pharmaceuticals,Non
[2] Biopharmaceutical Assessments CFU,clinical Drug Development
[3] Eisai Inc.,DMPK
[4] Eisai Inc.,Andover
[5] Biogen Idec,Development Quality Assurance
[6] 14 Cambridge Center,Department of Drug Metabolism and Pharmacokinetics
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
E6201; Pharmacokinetics; MEK1 inhibitor; Protein binding; CYP induction; CYP inhibition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：229 / 237
页数：8
相关论文
共 30 条
  • [1] Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species
    Kumar, Vipul
    Schuck, Edgar L.
    Pelletier, Robert D.
    Farah, Nadia
    Condon, Krista B.
    Ye, Meng
    Rowbottom, Christopher
    King, Belinda M.
    Zhang, Zhi-Yi
    Saxton, Philip L.
    Wong, Y. Nancy
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (01) : 229 - 237
  • [2] Discovery and characterization of E6201: A potent natural product -inspired synthetic MEK1 inhibitor
    Nomoto, Kenichi
    CANCER RESEARCH, 2009, 69
  • [3] PRECLINICAL PHARMACOKINETICS AND ALLOMETRIC SCALING OF E6201; A NOVEL MEK1 AND MEKKI KINASE INHIBITOR
    Kumar, Vipul
    Schuck, Edgar
    Condon, Krista
    Ye, Meng
    Rowbottom, Christopher
    Saxton, Philip
    Wong, Nancy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1124 - 1124
  • [4] E6201, a novel MEK1 inhibitor, suppresses the metastatic capability of triple-negative breast cancer cells
    Lee, Jangsoon
    Lim, Bora
    Choi, Kuicheon
    Pearson, Troy
    Paradiso, Linda
    Myers, Thomas
    Tripathy, Debu
    Ueno, Naoto T.
    CANCER RESEARCH, 2018, 78 (13)
  • [5] In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts
    Wu, Jiayi
    Nomoto, Kenichi
    Wang, John
    Kuznetsov, Galina
    Agoulnik, Sergei
    Shuck, Edgar
    Wong, Nancy
    Towie, Murray
    Schnaderbeck, Matthew
    Wu, Sara
    Littlefield, Bruce
    CANCER RESEARCH, 2009, 69
  • [6] Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer
    Jangsoon Lee
    Bora Lim
    Troy Pearson
    Kuicheon Choi
    Jon A. Fuson
    Chandra Bartholomeusz
    Linda J. Paradiso
    Thomas Myers
    Debu Tripathy
    Naoto T. Ueno
    Breast Cancer Research and Treatment, 2019, 175 : 339 - 351
  • [7] Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer
    Lee, Jangsoon
    Lim, Bora
    Pearson, Troy
    Choi, Kuicheon
    Fuson, Jon A.
    Bartholomeusz, Chandra
    Paradiso, Linda J.
    Myers, Thomas
    Tripathy, Debu
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (02) : 339 - 351
  • [8] In vitro antiproliferative activity of natural product-based MEK1 inhibitor E6201 against V600E BRAF-mutated cancer cell lines
    Nomoto, Kenichi
    Wang, John
    Wu, Jiayi
    Agoulnik, Sergei
    Kuznetsov, Galina
    Towle, Murray
    Schnaderbeck, Matthew
    Gusovsky, Fabian
    Shirota, Hiroshi
    Littlefield, Bruce
    CANCER RESEARCH, 2009, 69
  • [9] Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer
    Jangsoon Lee
    Bora Lim
    Troy Pearson
    Kuicheon Choi
    Jon A. Fuson
    Chandra Bartholomeusz
    Linda J. Paradiso
    Thomas Myers
    Debu Tripathy
    Naoto T. Ueno
    Breast Cancer Research and Treatment, 2019, 176 : 251 - 251
  • [10] Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases
    Gampa, Gautham
    Kim, Minjee
    Cook-Rostie, Nicholas
    Laramy, Janice K.
    Sarkaria, Jann N.
    Paradiso, Linda
    DePalatis, Louis
    Elmquist, William F.
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (05) : 658 - 666
123